A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
OHSU Knight Cancer Institute
AstraZeneca
AstraZeneca
Hoosier Cancer Research Network
AstraZeneca
AstraZeneca
AstraZeneca
NeoTX Therapeutics Ltd.
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Queen Mary University of London
Maastricht University Medical Center
IFOM ETS - The AIRC Institute of Molecular Oncology
Institute of Cancer Research, United Kingdom
Eli Lilly and Company
AstraZeneca
Seoul National University Hospital